Prostate Cancer Coalition of NC

A statewide collaborative effort by concerned organizations and individuals to support awareness, early detection, and “best practices” care for men who are,

or will someday be, prostate cancer survivors.

www.pccnc.org

Learning Objectives

1. Risk benefit discussion

2. Screening and prostate health

3. Early detection to support clinical treatment guidelines for patients that opt to screen

4. Tools to support informed pre-treatment consult for your patients

Risk Benefit Discussion

Risk Assessment Physical Exam & Baseline PSA Careful review of personal health and

family history A Thorough Understanding of the

Diagnostic and Decision Making Process

Risks

Screening can help identify, but is not specific to, prostate cancer.

65% of elevated PSA is caused by: other prostate health conditions activity known to artificially elevate PSA

Screening can be normal even when a man has prostate cancer.

Abnormal screening is NOT a cancer diagnosis. Every man diagnosed with prostate cancer should know to

consider personal health, priorities, and how aggressive his cancer is prior to evaluating treatment options.

Benefits

Can help identify several non-cancerous conditions. can become uncomfortable if left untreated

Only known method of detecting prostate cancer during its early stages.

Better options, and often more time to research and consider those options.

Evidence Based Healthcare

Johns Hopkins/ Cochrane Collaboration course, "Understanding evidence-based healthcare: A foundation for action."

PCP Clinical Practice Guidelines

Reflect NCCN guidelines applicable in a primary care setting

A convenient, evidence-based reference for evaluating screening results

Reviewed and supported by NC’s 3 National Cancer Institute (NCI)-designated Cancer Centers (Duke, UNC, and Wake Forest)

Referral Discussion Guide

Reflects American Urological Association “best practices” guidelines for follow up

Facilitates patient’s ongoing education and shared decision making

Newly Diagnosed Tutorial

Helps patient understand prognostic factors at diagnosis

Supports patient involvement and a multidisciplinary analysis of treatment options

Localized Pilot Program

Multi-disciplinary consultation encouraged and supported

Forms to support multi-institutional collaboration

Collaborate to Provide Leading Edge Research and the Best Possible Care for

those Affected by this Disease

Difficult cases discussed at local GU tumor board

When necessary, engage with academic centers

Moving Forward: Goals

Reduce the prostate cancer death rate

Continue to address gaps in patient education

Support personalized care Facilitate informed / shared decision

making

Conclusion: practical strategy

Avoid under-detection of aggressive/ potentially fatal cancers

Manage over-detection with the guidance of modern clinical treatment guidelines

Empower patients to be actively involved in treatment choice

Primary care physicians, urologists and oncologists work together